Michael Bourque

Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenia

Thomas J. Walsh, Hedy Teppler, Gerald R. Donowitz et al. · New England Journal of Medicine · 2004 · 921 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17

A Randomized, Double-Blind, Multicenter Study of Caspofungin Versus Liposomal Amphotericin B for Empiric Antifungal Therapy in Pediatric Patients With Persistent Fever and Neutropenia

Johan Maertens, Luís Madero, Anne F. Reilly et al. · The Pediatric Infectious Disease Journal · 2010 · 138 citations

Pharmacy, Infectious Diseases, Pediatrics +17

SAFETY EXPERIENCE WITH CASPOFUNGIN IN PEDIATRIC PATIENTS

Theoklis E. Zaoutis, Thomas Lehrnbecher, Andreas H. Groll et al. · The Pediatric Infectious Disease Journal · 2009 · 40 citations

Pharmacy, Pediatrics, Pharmacotherapy +15

Caspofungin Use in Patients with Invasive Candidiasis Caused by Common Non- <i>albicans Candida</i> Species: Review of the Caspofungin Database

Arnaldo Lopes Colombo, Angela Ngai, Michael Bourque et al. · Antimicrobial Agents and Chemotherapy · 2010 · 40 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +15

Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study

B.E. de Pauw, Carole A. Sable, Thomas J. Walsh et al. · Transplant Infectious Disease · 2006 · 32 citations

Pharmacy, Pharmacology, Pharmacotherapy +17